A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)

被引：3

作者：

Ahn, M. J. ^{[1
]}

Park, S. ^{[2
]}

Kim, T. M. ^{[3
]}

Han, J. Y. ^{[4
]}

Lee, G. W. ^{[5
,6
]}

Shim, B. ^{[7
]}

Lee, Y. G. ^{[8
]}

Kim, S. W. ^{[9
]}

Kim, I. H. ^{[10
]}

Lee, S. ^{[11
]}

Kim, Y. J. ^{[12
]}

Park, J. H. ^{[13
]}

Park, S. G. ^{[14
]}

Lee, K. H. ^{[15
]}

Kang, E. J. ^{[16
]}

Kim, J. W. ^{[17
]}

Shin, S. H. ^{[18
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Dept Hematol Oncol, Seoul, South Korea

[2] Samsung Med Ctr, Hematol & Med Oncol, Seoul, South Korea

[3] Seoul Natl Univ, Internal Med Dept, Coll Med, Yeongeon Med Campus, Seoul, South Korea

[4] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Ctr Lung Canc, Goyang, South Korea

[5] Gyeongsang Natl Univ Hosp, Internal Med Dept, Jinju, South Korea

[6] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea

[7] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Suwon, South Korea

[8] Kangbuk Samsung Hosp, Internal Med Dept, Samsung Med Ctr SMC, Seoul, South Korea

[9] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea

[10] Inje Univ Haeundae Paik Hosp, Med Oncol Dept, Busan, South Korea

[11] Dong A Univ, Internal Med, Med Ctr, Busan, South Korea

[12] SNUBH Seoul Natl Univ Bundang Hosp, Dept Internal Med, Seongnam, South Korea

[13] Konkuk Univ, Dept Med Oncol, Med Ctr, Seoul, South Korea

[14] Chosun Univ Hosp, Internal Med, Gwangju, South Korea

[15] Chungbuk Natl Univ Hosp, Internal Med, Cheongju, South Korea

[16] Korea Univ Guro Hosp, Dept Internal Med, Seoul, South Korea

[17] Korea Univ Anam Hosp, Dept Hematooncol, Seoul, South Korea

[18] Kosin Univ Gospel Hosp, Dept Internal Med, Busan, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.068

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA67

引用

页码：S1311 / S1311

页数：1